GSK/Vir’s Xevudy Begins EU Review For COVID-19

EMA Issues Scientific Opinion On Molnupiravir

Things are happening very quickly on the COVID-19 front, with sotrovimab, molnupiravir, Paxlovid and Novaxovid all under EU review for marketing authorization or emergency use, and EMA decisions expected on boosters and the use of vaccines in younger age groups.

Corona Virus symbol on blue yellow european union EU flag europe background.
Several vaccines and treatments for COVID-19 are under review in the EU • Source: Alamy

The European Medicines Agency has begun evaluating an approval application from GlaxoSmithKline and Vir for their monoclonal antibody, Xevudy (sotrovimab), for treating adults and adolescents with COVID-19 who do not require supplemental oxygen therapy and are at increased risk of progressing to severe disease.

The agency’s human drugs committee, the CHMP, has also issued a scientific opinion to EU member states wanting to grant...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography